Literature DB >> 8095395

Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines.

A van de Stolpe1, E Caldenhoven, J A Raaijmakers, P T van der Saag, L Koenderman.   

Abstract

Increased expression of the intercellular adhesion molecule-1 (ICAM-1) on cells present in the airways has been suggested to play a role in the pathogenesis of asthma by enhancing airway inflammation. We used the monocytic U937 cell line, both undifferentiated and differentiated to a macrophage-like phenotype, and the bronchial epithelial cell line NCI-H292 as cellular model systems for human monocytes/macrophages and bronchial epithelial cells, respectively, and studied the effects of 12-O-tetradecanoyl phorbol-13-acetate (TPA) and dexamethasone on ICAM-1 expression. Both cell lines expressed the ICAM-1 protein constitutively. In addition, TPA- or 1,25-dihydroxyvitamin D3-mediated differentiation of the U937 cell line into a macrophage-like phenotype was associated with increased expression of ICAM-1. In both cell lines, two ICAM-1 mRNA transcripts were found, and expression was stimulated to a similar degree within 1 to 2 h after addition of TPA. In both cell lines, the anti-inflammatory corticosteroid dexamethasone repressed both constitutive and TPA-stimulated ICAM-1 expression, within 3 h of its addition. In the presence of cycloheximide, a marked superinduction of ICAM-1 was observed, while the repressive effect of dexamethasone remained, supporting the hypothesis that dexamethasone acts directly at the transcriptional level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095395     DOI: 10.1165/ajrcmb/8.3.340

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  13 in total

Review 1.  Pharmacotherapy and airway remodelling in asthma?

Authors:  P A Beckett; P H Howarth
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

2.  The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain.

Authors:  R M Nissen; K R Yamamoto
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

3.  Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy.

Authors:  G Fingerle-Rowson; M Angstwurm; R Andreesen; H W Ziegler-Heitbrock
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

4.  Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids.

Authors:  K P Ray; S Farrow; M Daly; F Talabot; N Searle
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

Review 5.  [T-cell immune responses in chronic inflammatory diseases of the nasal mucosa].

Authors:  L Klimek; I Casper; S Siemer; B Wollenberg; R Stauber; M Koennecke
Journal:  HNO       Date:  2019-11       Impact factor: 1.284

Review 6.  Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.

Authors:  Magda Cepkova; Michael A Matthay
Journal:  J Intensive Care Med       Date:  2006 May-Jun       Impact factor: 3.510

7.  Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation.

Authors:  K De Bosscher; M L Schmitz; W Vanden Berghe; S Plaisance; W Fiers; G Haegeman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

8.  Corticosteroids and montelukast: effects on airway epithelial and human umbilical vein endothelial cells.

Authors:  K Andersson; E B Shebani; N Makeeva; G M Roomans; Z Servetnyk
Journal:  Lung       Date:  2010-01-16       Impact factor: 2.584

Review 9.  Intercellular adhesion molecule-1.

Authors:  A van de Stolpe; P T van der Saag
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

10.  Transcriptional regulation of intronic calcium-activated potassium channel SK2 promoters by nuclear factor-kappa B and glucocorticoids.

Authors:  Min-Jeong Kye; Joachim Spiess; Thomas Blank
Journal:  Mol Cell Biochem       Date:  2007-03-30       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.